Foldikines™: Reprogramming the Immune System Like Software Code
Cytokines are the immune system’s messengers, sending signals to direct immune responses. But in many diseases, these signals go wrong, much like in a faulty software program that starts producing errors.
Orikine Bio’s Foldikine™ platform works by engineering cytokines that act like "patches" in a malfunctioning computer program, fixing the faulty signals and restoring the immune system to its proper function.
News and events
Orikine Bio appoints Larry Edwards as Chairman of the Board
Barcelona, Spain, 20 January 2026. Orikine Bio, a biotechnology company based at the Barcelona Science Park (PCB-UB), today announced the appointment of Larry Edwards as Chairman of its Board of Directors, effective 1 January 2026. His incorporation strengthens the company’s governance and supports its strategic vision as it advances toward key clinical and corporate milestones.
20 January, 2026Orikine Bio Awarded €335K CDTI-Funded NEOTEC 2024 Grant to Advance Its Cytokine Engineering Platform
Orikine Bio has been awarded a €335k grant under the NEOTEC 2024 program, funded by the CDTI, to strengthen the development of its proprietary bi specific cytokine platform for severe autoimmune diseases. This highly competitive scheme supports technology driven companies with strong innovation potential, and the award recognizes Orikine’s scientific excellence and capacity to advance disruptive immunomodulatory solutions. The funding will accelerate critical development milestones and reinforce the company’s long term technology based growth strategy. Ranked among the Top 10 highest-rated NEOTEC projects in Spain.
17 December, 2024Orikine Bio secures €800k in innovation research funding to advance groundbreaking autoimmune disease therapy
Orikine Bio, a pioneering biopharmaceutical company focused on the discovery, research and development of precision-engineered bi-specific cytokine therapies for the treatment of severe autoimmune diseases, today announces the award of €800k ($868k) in funding from the CPP23 innovation health research program.
03 December, 2024
Join us
At Orikine Bio, we are pioneering the future of cytokine-based therapies, pushing the boundaries of science and biology to develop groundbreaking solutions for autoimmune and inflammatory diseases. Our success is driven by the passion, creativity, and scientific rigor of our team. If you are excited about joining a company at the forefront of biotechnology, where innovation meets impact, Orikine is the place for you.
Investors
This company is capitalized by INNVIERTE, AN INVESTMENT PROGRAM OF CDTI, E.P.E.
Grants
Project CPP2023-010468 financed by MICIU/AEI/10.13039/501100011033; Project CPP2024-011392 financed by MICIU/AEI/10.13039/501100011033
PTQ2022-012499 awarded by MCIU/AEI / 10.13039/501100011033; PTQ2023-012951 awarded by MICIU/AEI / 10.13039/501100011033
Project SNEO-20241312 financed by Centro para el Desarrollo Tecnológico y la Innovación E.P.E. (CDTI) in the context of Plan Estatal de Investigación Científica y Técnica y de Innovación